“The positive opinion of EMA about Acoziborole, a single dose treatment of the deadly human African trypanosomiasis (HAT) represents a major step forward. Our collaboration with PhinC was instrumental to the success of the project. They supported the program through population PK modeling to characterize drug exposure in HAT patients and quantify variability. This work helped identify intrinsic and extrinsic factors influencing pharmacokinetics. In addition, they conducted concentration-response analyses to support cardiac safety evaluation Their flexibility and expertise enabled us to obtain the right information at the right time to meet regulatory requirements.”

“Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity.”

“Crossject and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs.”